Read our ESMO Congress 2026 content (+++++)

ARTICLES Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open label, phase 3 trial in China Free with registration until Nov 4, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01899-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmo26&_hsenc=p2ANqtz-8PatPY-q5syDq5cRIEaodGLPJl6YwK3bAMIaCb30AjmF6TcS3uAY2RLxyx8U7acXNOZzFE0nVCKpkYgrnR9snyjL1uIw&_hsmi=445989026&utm_content=445989026&utm_source=hs_email 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan Free with registration until Nov 4, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01782-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmo26&_hsenc=p2ANqtz-_nIKpAwhV594yXgYYzY64WirU0zr_AxExT1vjUqR094_ebIUZUAxRn4M40OGF3ZGobOI77gyMwVKOM9_HrJ7Egfj4RBg&_hsmi=445989026&utm_content=445989026&utm_source=hs_email Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China Free with registration until Nov 4, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02026-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmo26&_hsenc=p2ANqtz--4WcK9QQqJxacnaGsorwRDGMTkmbA_t_cDgRH-3ws5M_ec5vg-vDrnyMFxA-oHChkvaKOu9547FfxzTB6koT762wa-Ng&_hsmi=445989026&utm_content=445989026&utm_source=hs_email Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial Free with registration until Nov 4, 2026 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00446-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmo26&_hsenc=p2ANqtz-9CMdTnEx56qrqktZWxDpyFMzdjXsigEZnhqtw3f8p0Z5d8OjvqQ2eZyn71nJ8Pu3_zXySq8QBDZkXpufSRovTsAic70w&_hsmi=445989026&utm_content=445989026&utm_source=hs_email An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial Open Access https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00304-9/fulltext?dgcid=hubspot_email_conferencealerts_esmo26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_8_vinwlzYx-4XETdJE5x1KfLxIUjXo7MgrvAQo1VfUyuZ9exbcO_JikI8XwCXpnIIWIaJcMRIas7YlxToAghQI0nk7Q&_hsmi=445989026&utm_content=445989026&utm_source=hs_email